Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
54 hedge funds and large institutions have $18.3M invested in Northwest Biotherapeutics, Inc. Common stock in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
15% less capital invested
Capital invested by funds: $21.4M → $18.3M (-$3.15M)
16% less funds holding
Funds holding: 64 → 54 (-10)
53% less call options, than puts
Call options by funds: $110K | Put options by funds: $233K
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$95.6K |
| 2 |
CDH
Charles D. Hyman
|
+$93.4K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$22.1K |
| 4 |
Goldman Sachs
New York
|
+$16.6K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$512K |
| 2 |
Renaissance Technologies
New York
|
-$495K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$195K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$109K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$108K |
NWBO Hedge Fund Activity: Q3 2016 in Review
54 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2016, worth a combined $18.3M — down 15% from $21.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NWBO and 6 opened new positions — a net loss of 10 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was Creative Planning, adding an estimated $95.6K. The largest seller was Sabby Management, exiting entirely with an estimated $512K sold.
- 54 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2016, down from 64 in Q2 2016.
- Funds reported $18.3M of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2016, down 15% quarter-over-quarter.
- 6 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2016 and 16 closed out, a net change of -10 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2016 was Creative Planning, an estimated $95.6K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2016 was Sabby Management, an estimated $512K sold.
Based on aggregated 13F filings for Q3 2016.